Boston Life Sciences Moves into New Headquarters.HOPKINTON, Mass. -- Boston Life Sciences, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BLSI BLSI Boston Life Sciences, Inc. ) today announced that it has relocated to new headquarters in Hopkinton, Massachusetts, and subleased its former headquarters on Newbury Street in Boston. It is anticipated that the relocation will afford the Company several benefits. The relocation is expected to reduce on-going overhead expenses for facility operation which the company believes will allow a greater share of financial resources to be devoted to program and business development. Subleases for the Newbury Street facility were finalized and delivered on September 9, 2005 with tenants that have agreed to lease the facility for the remainder of the existing lease terms. The lease for the Hopkinton headquarters expires in June 2008 providing the Company with increased flexibility and expansion possibilities going forward. Hopkinton is located 26 miles southwest of Boston. The town provides a biotech friendly environment easily accessible from both Boston and Providence airports. The Company will also maintain additional short term leased office space in Woburn, Massachusetts to accommodate certain research and administrative personnel. The Company's new postal address and phone numbers are as follows: Boston Life Sciences, Inc. 85 Main Street Hopkinton, MA 01748 Tel: (508) 497-2360 Fax: (508) 497-9964 The current website and email address will remain the same: Website: http://www.bostonlifesciences.com Email: IR@bostonlifesciences.com About Boston Life Sciences Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS See Continuous net settlement. CNS See continuous net settlement (CNS). ) disorders. ALTROPANE molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinsonian Syndrome (PS) and a Phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II for the diagnosis of Attention Deficit Hyperactivity Disorder attention deficit hyperactivity disorder (ADHD), formerly called hyperkinesis or minimal brain dysfunction, a chronic, neurologically based syndrome characterized by any or all of three types of behavior: hyperactivity, distractibility, and impulsivity. (ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) Definition Attention-deficit/hyperactivity disorder (ADHD) is a developmental disorder characterized by distractibility, hyperactivity, impulsive behaviors, and the inability to remain focused on tasks or ). The Company's research and pre-clinical CNS programs include Inosine inosine /in·o·sine/ (I) (in´o-sen) a purine nucleoside containing the base hypoxanthine and the sugar ribose, which occurs in transfer RNAs and as an intermediate in the degradation of purines and purine nucleosides to uric acid and in for the treatment of stroke, O-1369 for the treatment of Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. and FLUORATEC(TM), a second generation molecular imaging agent, for PS and ADHD. BLSI's current research collaborations include Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. , Children's Hospital of Boston and the University of Massachusetts-Worcester. The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Forward-looking statements include statements regarding Boston Life Sciences' expectations, beliefs, intentions or strategies regarding the future and can be identified by terminology such as "anticipate," "believe," "could," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Quarterly Report on form 10-Q Form 10-Q See 10-Q. for the quarter ended June 30, 2005, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Boston Life Sciences from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Boston Life Sciences, Inc. is providing the information in this press release as of this date and does not undertakes any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. ALTROPANE is a registered trademark and FLUORATEC is a trademark of Boston Life Sciences, Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion